CFTX 2034
Alternative Names: CFTX-2034; SSTR5 agonist - Confo TherapeuticsLatest Information Update: 30 Dec 2025
At a glance
- Originator Confo Therapeutics
- Class Antibodies; Antihypoglycaemics
- Mechanism of Action Somatostatin receptor 5 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypoglycaemia
- Research Hyperinsulinaemia
Most Recent Events
- 18 Dec 2025 Preclinical trials in Hypoglycaemia in Belgium (Parenteral) prior to December 2025
- 18 Dec 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Hypoglycaemia released by Confo Therapeutics
- 31 Jul 2024 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide, prior to July 2024 (Confo Therapeutics website, July 2024)